Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA Approves Subcutaneous Keytruda as Pharmaceutical Giants Make Strides in Cancer and Rare Disease Treatments

FDA Approves Subcutaneous Keytruda as Pharmaceutical Giants Make Strides in Cancer and Rare Disease Treatments

The pharmaceutical industry has seen significant advancements in recent days, with major players securing regulatory approvals and reporting promising clinical trial results. From new drug delivery methods to potential breakthroughs in rare diseases, these developments underscore the sector's ongoing innovation and commitment to addressing unmet medical needs.

NoahAI News9/23/2025
Patient Square Capital to Acquire Premier Inc. in $2.6B Deal, Taking Healthcare Services Giant Private

Patient Square Capital to Acquire Premier Inc. in $2.6B Deal, Taking Healthcare Services Giant Private

Premier Inc., a leading healthcare group purchasing organization and technology-enabled intelligence provider, has agreed to be acquired by Patient Square Capital in a $2.6 billion deal that will take the company private. The transaction, announced on Monday, marks a significant shift for Premier, which has been publicly traded since 2013.

NoahAI News9/23/2025
Catalent Unveils New Global Headquarters as Novo Acquisition Anniversary Approaches

Catalent Unveils New Global Headquarters as Novo Acquisition Anniversary Approaches

Catalent, a leading contract development and manufacturing organization (CDMO), has marked a significant milestone in its corporate journey by inaugurating its new global headquarters in Tampa, Florida. This move comes as the company approaches the one-year anniversary of its acquisition by Novo Holdings, a subsidiary of the Novo Nordisk Foundation.

NoahAI News9/23/2025
Bristol Myers Squibb Reports Positive Phase 3 Results in Multiple Myeloma Trial

Bristol Myers Squibb Reports Positive Phase 3 Results in Multiple Myeloma Trial

Bristol Myers Squibb (BMS) has announced a significant breakthrough in its phase 3 multiple myeloma trial, marking an end to a series of recent setbacks in the company's R&D efforts. The study, which evaluated the combination of BMS's investigational cereblon E3 ligase modulator iberdomide with Darzalex and dexamethasone, has met one of its dual primary endpoints, showing statistically significant improvement in minimal residual disease (MRD) negativity rates.

NoahAI News9/23/2025
Roche Unveils Ambitious Obesity Strategy, Aiming for Top 3 Position by 2030

Roche Unveils Ambitious Obesity Strategy, Aiming for Top 3 Position by 2030

Roche, the Swiss pharmaceutical giant, has laid out a comprehensive strategy to become one of the top three companies in the rapidly growing obesity treatment market. The ambitious plan, revealed during the company's recent Pharma Day presentation, marks a significant shift in Roche's approach to tackling the global obesity epidemic.

NoahAI News9/23/2025
Xoma Leads Charge in Liquidating Biotech 'Zombies' Amid Industry Shake-up

Xoma Leads Charge in Liquidating Biotech 'Zombies' Amid Industry Shake-up

The pharmaceutical industry is witnessing a significant shift as drug royalty firm Xoma spearheads a wave of liquidations targeting struggling biotech companies. This trend, emerging from the aftermath of the COVID-19 biotech boom, is reshaping the landscape of the industry and raising questions about the future of drug development.

NoahAI News9/23/2025
Merck Expands AI Capabilities with $349M Variational AI Deal

Merck Expands AI Capabilities with $349M Variational AI Deal

Merck & Co. has significantly bolstered its artificial intelligence (AI) capabilities in drug discovery through a new collaboration with Variational AI. The deal, worth up to $349 million, aims to leverage AI technology to tackle challenging drug targets and accelerate small molecule development.

NoahAI News9/23/2025
Manufacturing Investments Surge as Pharmaceutical Companies Prepare for Obesity Drug Market

Manufacturing Investments Surge as Pharmaceutical Companies Prepare for Obesity Drug Market

In a significant shift within the pharmaceutical industry, companies are making substantial early-stage investments in manufacturing capacity to prepare for the burgeoning obesity drug market. This proactive approach marks a departure from traditional development strategies, with both small biotechs and large pharmaceutical firms positioning themselves to compete in a space currently dominated by Eli Lilly and Novo Nordisk.

NoahAI News9/23/2025
FDA Extends Review of Sanofi's Oral Multiple Sclerosis Drug Tolebrutinib

FDA Extends Review of Sanofi's Oral Multiple Sclerosis Drug Tolebrutinib

The U.S. Food and Drug Administration (FDA) has extended its review period for Sanofi's oral multiple sclerosis drug tolebrutinib, pushing the decision date from September 28 to December 28, 2025. This extension comes as a result of additional data submitted by Sanofi, which the FDA considers a major amendment to the new drug application (NDA).

NoahAI News9/23/2025
CVS's Omnicare Division Files for Bankruptcy Amid $949 Million Federal Judgment

CVS's Omnicare Division Files for Bankruptcy Amid $949 Million Federal Judgment

CVS Health Corporation's pharmacy services subsidiary, Omnicare, has filed for Chapter 11 bankruptcy protection following a substantial federal judgment over improper billing practices. The move comes as the long-term care pharmacy provider grapples with financial challenges and seeks to reorganize its operations.

NoahAI News9/23/2025
Pfizer Makes $4.9B Bid for Metsera, Renewing Obesity Drug Ambitions

Pfizer Makes $4.9B Bid for Metsera, Renewing Obesity Drug Ambitions

Pfizer has announced a $4.9 billion acquisition of Metsera, a move that signals the pharmaceutical giant's renewed commitment to the burgeoning obesity drug market. The deal, which could potentially reach $7.3 billion with additional milestone payments, comes after a series of setbacks in Pfizer's internal obesity drug development efforts.

NoahAI News9/23/2025
Trump Administration to Announce Controversial Autism Findings, Propose Tylenol Warning and Potential Treatment

Trump Administration to Announce Controversial Autism Findings, Propose Tylenol Warning and Potential Treatment

In a move that has sparked intense debate within the medical community, the Trump administration is set to announce what it claims to be a breakthrough in understanding and treating autism. The announcement, scheduled for a White House press conference this afternoon, is expected to link Tylenol use during early pregnancy to autism and propose a potential treatment using leucovorin, a medication typically used to counter chemotherapy toxicity.

NoahAI News9/23/2025
«1...515253...67»